Open Outbreak

Ebolavirus and Marburgvirus

Also known as: filoviruses, Ebola virus disease, EVD, Marburg virus disease, MVD, Filoviridae

Ebolavirus and Marburgvirus are members of the filovirus family. They can cause severe viral haemorrhagic fever in people and other primates. Illness usually starts suddenly with fever and other flu-like symptoms, then can progress to vomiting, diarrhoea, bleeding, shock, and organ failure in some patients. Spread is mainly through direct contact with blood, vomit, stool, or other body fluids from a sick person, or from contaminated items and unsafe burials. These viruses are not mainly spread through casual airborne contact in the way flu is. Reported case fatality varies widely by outbreak, but filovirus outbreaks have often been severe. For Ebola disease, reviews report overall fatality ranges around 25% to 90%, and licensed vaccines and antibody treatments now exist for at least one Ebola species, Zaire ebolavirus. For Marburg, WHO outbreak notices in 2025 and 2026 still described response based on surveillance, infection control, and supportive care, with no approved vaccine or specific treatment noted in the sources used here. Outbreaks have been sporadic, mostly in sub-Saharan Africa.

Key facts

TransmissionDirect contact with blood or other body fluids from a sick person; contact with contaminated objects; and exposure during unsafe care or burial. Ebola sources also note animal-to-human spillover, with bats implicated.
IncubationEbola: 2 to 21 days is widely used in WHO outbreak practice; Marburg: WHO used 21-day contact follow-up and 42 days for two incubation periods, implying an incubation period up to 21 days.
Case fatalityFilovirus outbreaks reported in the literature range from 25% to 90%. WHO notices for the 2026 Bundibugyo Ebola outbreak in DRC reported crude CFR 48.3% to 48.7%. WHO notices for Marburg in Tanzania in 2025 reported 100% in that outbreak, while Ethiopia's 2025-2026 outbreak was 14 deaths among 19 total cases reported to WHO.
Reproduction numberunknown
VaccineLicensed vaccines exist for Ebola virus disease indications, especially Zaire ebolavirus; no approved Marburg vaccine was identified in the sources used here.
TreatmentEbola: monoclonal antibody therapeutics are approved for some Ebola virus disease indications, alongside supportive care. Marburg: supportive care is the main treatment in the sources used here; no approved specific antiviral or antibody treatment was identified.
ReservoirBats are implicated as a reservoir or source for at least some ebolaviruses; the sources used here do not give a single confirmed reservoir statement for all filoviruses.
Endemic regionsSporadic outbreaks occur mainly in sub-Saharan Africa, especially central and eastern Africa in the recent WHO record reviewed here.

Transmission

These viruses spread mainly through close contact, not ordinary casual contact across a room. The clearest risk is direct contact with the blood or other body fluids of someone who is ill. That includes vomit, diarrhoea, and fluids on bedding, clothing, or medical equipment. Healthcare settings and funerals can become high-risk when gloves, protective equipment, safe cleaning, or safe burial practices are missing. A review of Ebola transmission notes that high viral loads in body fluids allow efficient spread by contact. The same review literature and WHO outbreak reports show how transmission grows when cases are detected late and when community deaths happen outside care. For Ebola, animal-to-human spillover is also part of the picture, with bats mentioned in the literature as a likely source. The sources used here do not provide a firm single reproduction number for filoviruses overall, so that figure is best treated as unknown.

Symptoms and severity

Illness usually begins suddenly. Early symptoms are often fever and a strong feeling of being unwell. People may then develop weakness, headache, muscle pain, vomiting, and diarrhoea. In severe cases, the disease can lead to shock, organ failure, and bleeding. The older Ebola review in The Lancet describes Ebola as a severe viral haemorrhagic fever. More recent filovirus reviews say reported case fatality rates across outbreaks have ranged from about 25% to 90%, which shows how much severity can differ by virus species, outbreak conditions, and access to care. WHO’s current outbreak notices show this clearly. In the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo, WHO reported a crude case fatality ratio near 48% in late 2026. In Marburg outbreaks, WHO reported 100% for Tanzania in 2025, while Ethiopia’s 2025 to 2026 outbreak had 19 total cases with 14 deaths reported to WHO.

Treatment and vaccines

Care starts with the basics: rapid diagnosis, fluids, support for breathing and blood pressure when needed, treatment of complications, and strict infection control. For Ebola, the picture has improved. A 2022 review states that the push after the West Africa epidemic led to regulatory approval of two vaccines and two therapeutics for Ebola virus disease indications. A 2024 review also describes monoclonal antibody treatment as an important advance for Ebola disease. But this does not mean every Ebola type has the same tools. The sources used here do not support saying that all ebolaviruses have licensed vaccines or treatments. For Marburg, the evidence gathered here does not identify any approved vaccine or specific treatment. WHO’s Marburg outbreak notices focused on supportive care, contact tracing, surveillance, and infection prevention rather than a licensed countermeasure. So the short version is: some Ebola infections now have vaccine and treatment options, while Marburg still relies mainly on supportive care and outbreak control.

Where it occurs

The sources reviewed here point to sub-Saharan Africa as the main area where human outbreaks occur. An Ebola review in The Lancet says Ebola viruses are endemic in regions of central Africa, with Reston ebolavirus as an exception found in the Philippines and not associated with human disease in that source. More recent filovirus reviews describe sporadic outbreaks in sub-Saharan Africa. WHO outbreak notices from 2025 and 2026 show current activity concentrated in eastern and central African settings: Bundibugyo Ebola in the Democratic Republic of the Congo, with imported cases reported in Kenya and Nigeria in 2026, and Marburg outbreaks in Ethiopia and the United Republic of Tanzania in 2025 to 2026. This pattern matters because border crossings, referral hospitals, and travel routes can spread risk beyond the first affected district. Still, the evidence used here does not support calling filoviruses globally endemic. The best plain-language description is that they appear in outbreaks, mainly in parts of Africa, with occasional international spread through travel.

Recent history

This site’s archive count for the pathogen key provided here is 0, so there are no older archived events on this site to summarise. In the current WHO Disease Outbreak News record reviewed for this page, filoviruses have remained active. For Ebola, WHO reported a large Bundibugyo virus disease outbreak in the Democratic Republic of the Congo through 2026, with sustained transmission and cross-border concern after imported cases reached Kenya and Nigeria. WHO assessed the risk in the Democratic Republic of the Congo as very high in those late-2026 notices. For Marburg, WHO reported an outbreak in Tanzania in early 2025, later declared over on 2025-03-13, and a separate outbreak in Ethiopia that was declared over on 2026-01-26 after two incubation periods with no further cases. Taken together, the recent picture is not one of constant worldwide spread, but of repeated outbreaks in Africa, some of them severe, with occasional exportation to neighbouring countries.

What to watch

Several signals would make filoviruses more concerning. First is spread into new regions or dense cities, especially when cases are detected late or move across borders. WHO’s 2026 Ebola notices already show why: imported cases in Kenya and Nigeria widened concern beyond the original outbreak area. Second is clearer, sustained human-to-human transmission in hospitals, households, or funerals, particularly when many community deaths happen before isolation. Third is a mismatch between the virus and available tools. The treatment and vaccine gains described in the literature are strongest for some Ebola disease indications, not for Marburg and not equally for every ebolavirus species. Fourth is supply and access: even effective products help only if they can be delivered quickly where outbreaks start. Finally, any sign that standard infection-control measures are failing, or that surveillance and contact tracing cannot keep up, would raise the risk of larger outbreaks. Those are the practical warning signs public health teams watch most closely.

Related outbreaks

Updated